atomoxetine hydrochloride has been researched along with Parkinson Disease in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 5 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ciucci, MR; Hoffmeister, JD; Kelm-Nelson, CA | 1 |
| Barker, RA; Hezemans, FH; Holland, N; Jones, PS; Murley, AG; O'Callaghan, C; Passamonti, L; Regenthal, R; Robbins, TW; Rowe, JB; Rua, C; Tsvetanov, KA; Williams-Gray, CH; Wolpe, N; Ye, R | 2 |
| Biaggioni, I; Celedonio, JE; Kaufmann, H; Martinez, J; Palma, JA; Shibao, CA | 1 |
| Brown, JN; Ottman, AA; Warner, CB | 1 |
| Al-Enezi, N; AlShalabi, SR; Naguy, A | 1 |
| Altena, E; Barker, RA; Housden, CR; Huddleston, C; Maxwell, H; Nombela, C; Rae, CL; Regenthal, R; Rittman, T; Robbins, TW; Rowe, JB; Sahakian, BJ; Ye, Z | 1 |
| Barker, RA; Housden, CR; Kehagia, AA; Müller, U; Regenthal, R; Robbins, TW; Rowe, J; Sahakian, BJ | 1 |
| Biaggioni, I; Jordan, J; Shibao, C | 1 |
| Altena, E; Barker, RA; Coyle-Gilchrist, I; Ham, T; Housden, CR; Jones, PS; Maxwell, H; Nombela, C; Rae, CL; Regenthal, R; Rittman, T; Robbins, TW; Rodríguez, PV; Rowe, JB; Sahakian, BJ; Ye, Z | 1 |
| Borchert, RJ; Hughes, LE; Jones, SP; Nombela, C; Passamonti, L; Rae, CL; Rittman, T; Robbins, TW; Rowe, JB; Sami, S; Vatansever, D; Vázquez Rodríguez, P; Ye, Z | 1 |
| Barker, RA; Coyle-Gilchrist, I; Ham, T; Hughes, LE; Jones, PS; Nombela, C; Rae, CL; Regenthal, R; Rittman, T; Robbins, TW; Rodríguez, PV; Rowe, JB; Sahakian, BJ; Ye, Z | 1 |
| Biglan, K; Gerstenhaber, M; Marsh, L; Williams, JR | 1 |
| Jankovic, J | 1 |
| Colcher, A; Duda, JE; Horn, SS; Hurtig, HI; Mamikonyan, E; Mavandadi, S; Nazem, S; Siderowf, AD; Stern, MB; Ten Have, TR; Weintraub, D | 1 |
1 review(s) available for atomoxetine hydrochloride and Parkinson Disease
| Article | Year |
|---|---|
The Role of Atomoxetine for Parkinson Disease-Related Executive Dysfunction: A Systematic Review.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Cognitive Dysfunction; Executive Function; Humans; Parkinson Disease | 2018 |
8 trial(s) available for atomoxetine hydrochloride and Parkinson Disease
| Article | Year |
|---|---|
Noradrenergic deficits contribute to apathy in Parkinson's disease through the precision of expected outcomes.
Topics: Apathy; Atomoxetine Hydrochloride; Cross-Over Studies; Humans; Norepinephrine; Parkinson Disease | 2022 |
Improving response inhibition in Parkinson's disease with atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Aged; Aged, 80 and over; Atomoxetine Hydrochloride; Brain; Choice Behavior; Cognition Disorders; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Image Processing, Computer-Assisted; Inhibition, Psychological; Male; Middle Aged; Neural Pathways; Neuropsychological Tests; Oxygen; Parkinson Disease; Reaction Time | 2015 |
Targeting impulsivity in Parkinson's disease using atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Aged; Atomoxetine Hydrochloride; Attention; Decision Making; Double-Blind Method; Female; Games, Experimental; Humans; Impulsive Behavior; Inhibition, Psychological; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Parkinson Disease; Propylamines; Reaction Time; Verbal Learning | 2014 |
Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures.
Topics: Adrenergic Uptake Inhibitors; Aged; Atomoxetine Hydrochloride; Brain; Citalopram; Cross-Over Studies; Double-Blind Method; Female; Humans; Inhibition, Psychological; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Parkinson Disease; Prognosis; Psychomotor Performance; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors | 2016 |
Atomoxetine restores the response inhibition network in Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Aged; Atomoxetine Hydrochloride; Corpus Striatum; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Executive Function; Female; Humans; Inhibition, Psychological; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Net; Outcome Assessment, Health Care; Parkinson Disease; Prefrontal Cortex; Severity of Illness Index | 2016 |
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antiparkinson Agents; Atomoxetine Hydrochloride; Bipolar Disorder; Cognition Disorders; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Nootropic Agents; Parkinson Disease; Pilot Projects; Prefrontal Cortex; Propylamines; Psychological Tests; Psychotropic Drugs; Severity of Illness Index; Treatment Outcome | 2009 |
Atomoxetine for freezing of gait in Parkinson disease.
Topics: Adrenergic Uptake Inhibitors; Aged; Antiparkinson Agents; Atomoxetine Hydrochloride; Double-Blind Method; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Propylamines; Severity of Illness Index | 2009 |
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease.
Topics: Adrenergic Uptake Inhibitors; Aged; Atomoxetine Hydrochloride; Cognition Disorders; Comorbidity; Depression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Parkinson Disease; Propylamines; Psychiatric Status Rating Scales; Severity of Illness Index; Sleep Wake Disorders; Time Factors; Treatment Outcome | 2010 |
6 other study(ies) available for atomoxetine hydrochloride and Parkinson Disease
| Article | Year |
|---|---|
Manipulation of vocal communication and anxiety through pharmacologic modulation of norepinephrine in the Pink1-/- rat model of Parkinson disease.
Topics: Adrenergic Uptake Inhibitors; Animals; Anxiety; Atomoxetine Hydrochloride; Disease Models, Animal; Humans; Male; Norepinephrine; Parkinson Disease; Protein Kinases; Rats; Rats, Long-Evans; Reboxetine; Vocalization, Animal | 2022 |
Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Aged; Atomoxetine Hydrochloride; Double-Blind Method; Female; Humans; Inhibition, Psychological; Locus Coeruleus; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Reaction Time | 2021 |
Predictors of the Pressor Response to the Norepinephrine Transporter Inhibitor, Atomoxetine, in Neurogenic Orthostatic Hypotension.
Topics: Adrenergic Uptake Inhibitors; Aged; Atomoxetine Hydrochloride; Blood Pressure; Female; Humans; Hypotension, Orthostatic; Male; Middle Aged; Multiple System Atrophy; Norepinephrine; Parkinson Disease; Pure Autonomic Failure; Retrospective Studies | 2021 |
Atomoxetine in-focus!
Topics: Atomoxetine Hydrochloride; Humans; Mental Disorders; Neurodevelopmental Disorders; Neurotransmitter Uptake Inhibitors; Parkinson Disease | 2020 |
Multiple system atrophy: using clinical pharmacology to reveal pathophysiology.
Topics: Atomoxetine Hydrochloride; Autonomic Nervous System; Clonidine; Diagnosis, Differential; Drug Therapy; Humans; Indole Alkaloids; Multiple System Atrophy; Parkinson Disease; Pure Autonomic Failure; Pyridostigmine Bromide; Trimethaphan | 2015 |
Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease.
Topics: Adrenergic Uptake Inhibitors; Aged; Atomoxetine Hydrochloride; Brain Mapping; Cross-Over Studies; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Parkinson Disease; Prefrontal Cortex | 2016 |